We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Up 20% now
Dallo
Thank you for letting us know that the research note is out, please can you provide a link.
I agree that our assets are so undervalued. How can we be at 10m with a drug in phase 3 trials and we have tje other 2 assets and we all know the great news we receieved yesterday.
We march onwards! And boy does this share move when it moves.
Gla
So if we are being optimistic then Immupharma is just valued at its investment in Incanthera and all the rest is valued at zero.
Interesting.
Major research note from Stanford Partners plus Interview with McCarthy on Incanthera just out.
Stanford postulates 2 scenarios ..one with just the European market for Sol with revenues of $35m and then secondly, expansion into Asia with revenues of c$100m by 2026/7.
It is on the Incanthera website.
If Stanford is right Incanthera could be worth north of $100m.
DYOR
I think nolupus just likes a bit of attention. On the subject of seeing the other side Dallo - what’s the situation with the patents at the minute? Have they got a plan to extend? From memory, US expires 2026, Europe has a bit longer - something like 2032 - both from memory and happy to be corrected.
“Imm invested £2.25 million into Incanthera and they are still on a papier loss on that investment AT this Time…” But so what, nolupus? The thing that matters is whether the value of the incanthera asset was priced in to the valuation of Imm stock. The point that it trades at a paper loss is rather irrelevany if that loss was already priced in to Imm stock… You say you can see the potential here - why not tell us about that?
Wildbunch
Sadly old Nolupus doesn't seem himself recently with garbled posts full of spelling errors , capital letters and
fuzzy thinking..
I sincerely hope he is okay as we have had some interesting debates over the past 8 years.
As for Immupharma having to come up with the cash to exercise the warrants it can simply sell some of its 9.9 m shares in Incanthera to pay for them particularly should Incanthera's SP soar to say 50p or higher.
As for his contention regarding the " book value": of Immupharma's investment in Incanthera it only has to do a mark to market valuation at the Interims and Final Accounts stages and show the realised/ unrealised gains or losses then.
Anyway I wish Nolupus the best as it is only a share board after all.
Nolupus
Did you mean nit picking when you wrote knit picking? Also earlier you wrote DID'NT-didn't you mean didn't?
So important to be accurate do you not think when discussing such very strong buys.
GLA
Dallo,
I think WE all agree on the future potential in Incanthera and IMM.
WE are knit picking but there is a Big différence between what IS in Imm accounts AT this Time and what there will be in the future IF they exercice the warrants.
Imm need Cash to exercice these warrants .
Have a look AT the COMPANY accounts to and the BOOK values before stating that i am mistaken 'once AGAIN ''
Looking forward to the growth of imm.
I feel an update on Lupuzor are due
Hi Dallo, I agree with you, combining the value of the direct shares and the potential from the warrants can result in a net unrealised gain for ImmuPharma, especially considering the upside potential of the warrants.
Let's delve into how these warrants could significantly contribute to ImmuPharma's value, especially with Incanthera's growth trajectory and potential acquisition scenarios.
Understanding the Warrants
ImmuPharma holds 7.3 million warrants in Incanthera, exercisable at any time, which is a testament to ImmuPharma's strategic investment acumen. These warrants represent a right but not an obligation to purchase additional shares at a predetermined price, in this case, 9.5p. Given Incanthera's top share price of 18p this morning, these warrants already hold considerable unrealised value.
Current Value and Future Potential
-Current Value Analysis:
Incanthera Share Price: 18p
Warrant Exercise Price: 9.5p
Difference: 8.5p per share
With 7.3 million warrants, this difference suggests an immediate potential unrealized gain of approximately £620,500 for ImmuPharma, should these warrants be exercised at 18p. This calculation alone highlights the immediate upside potential.
-Future Growth Potential:
Incanthera's journey, particularly with its expanding portfolio and promising revenue projections, speaks volumes about its market potential. A takeover scenario, where Incanthera could be valued at, let's speculate, 100p per share, would dramatically increase the value of ImmuPharma's position.
Takeover Scenario Value:
Hypothetical Takeover Price: 100p
Gain per Warrant: 90.5p (after deducting the exercise price of 9.5p)
Total Gain from Warrants: £6,606,500 (Let's bear in mind the unused tax losses of £49,025,230 as of 31.12.2022 available for offset against future profits)
This speculative analysis does not just reflect the potential financial windfall but underscores the strategic importance of holding these warrants. The anticipation of Incanthera's growth, coupled with the biopharmaceutical sector's dynamism, where acquisitions are frequent for promising companies, makes this scenario a thrilling possibility.
Looking Ahead
ImmuPharma's investment in Incanthera, including its significant warrants holding, is a pivotal part of its long-term growth strategy. The biopharmaceutical industry is ripe with innovation and consolidation, making the potential for Incanthera's acquisition at a premium not just bullish but a plausible future event. This not only could result in substantial financial gains for ImmuPharma but also validate its strategic investment approach.
For long-term investors in ImmuPharma, this scenario paints a picture of significant upside potential, not just from its core operations but also from savvy investment decisions. The anticipated developments in Incanthera, from commercial success to possible acquisition offers, represent an exciting horizon.
This is my personal opinion, n
Dallo. I tried to say the same thing to him but looks like it fell on deaf ears !
" The outlook for the Incanthera share price based on the revenue forecasts is extraordinarily bullish"
Dallo
it is a great commercial deal .....but whilst I see significant revenue, the profit will be less significant simply because they will sub-contract the Manufacturing, quality control and packaging , which is to be expected ..plus the marketing and distribution costs which is being done by Incanthera's wholly owned new subsidiary
It really depends on volume and good repeat orders and the volume can come as the number of stockists increases
Profit I suspect will come through more in year 2 once the product has some established customer experience and initial marketing spend
This doubling of an initial order announcement is common... I think they probably set it up like that...I have seen that before on other new product launches to create the excitement of demand
A super client relationship with which to grow from though
This was up 55% on a RNS - which, whilst some loved - some said was a bit 'so-so'. Well whatever you think of this RNS just imagine what will happen if IMM release an RNS which is perceived as being unequivocally good - re trials and or licensing -then sp should go up more than 55%.
Nolupus
Have you not read the Incanthera RNS.
The warrants held by Immupharma represent an unrealised gain based on Incanthera's current SP.
The 9.9m direct holding is an unrealised loss.
The two Immupharma holdings, shares and warrants in Incanthera combined have a net unrealised gain.
This could change depending on Incanthera's SP.
The outlook for the Incanthera share price based on the revenue forecasts is extraordinarily bullish.
Even you must admit that the prospects for our investment in Incanthera looks excellent after today's update.
66 messages ,all means nothing except ,PRICE & VOLUME
ARE THE WARRANTS guaranteed cash ? I not up to date on warrants . SO tims company will pay imm the money? IMO they would need to be drip feed
Dallo,
My statement DID'nt ignore anything..
The warrants have no BOOK value as you know, until exercised ...
They may have the potential to make IMM Money if exercised but that cannot be guaranteed as yet
Goldgirl's posts - laughable
3 assets but 10m mcap
Laughable
5Rings
Here is to a great ride up lol
Https://www.share-talk.com/rns-hotlist-with-zak-mir-i3e-casp-imm-sol-cobr-knb-gcm-neo-mka-pow-uee-kefi-opti-lex-urah/
Marionnaud.
Comment: INC was and is a jewel in the crown for IMM. We should expect the company to revamp the enthusiasm seen surrounding the stock at the start of 2024 shortly.
Nolupus
Your statement ignores the value of Immupharma's 7.3 m warrants at 9.5p exercisable at any time in Incanthera.
I agree with GoldGirl. When IMM trial didn't go well likely due to patient selection not being precise, Tim as chairman and CEO faced the shareholders to explain was to be commended. They have a good solution which involves exquisite biomarkers. Don't know if anyone notice but this biomarker correlated with positive outcomes in pre-clinical also. This story is only getting better.
Imm invested £2.25 million into Incanthera and they are still on a papier loss on that investment AT this Time....
Dallo , as you are the "accountant", please let me know , what IS wrong With my statement ?
My posts seems to bother many of you 'strong buy' ' crowd but whatever, i won't be put off by any lies or diffamatory comments .